Skip to main content

Table 4 Univariate analysis of the prognostic value of miR-125b-5p expression levels in relation to relapse-free survival in different hormone receptor–positive breast cancers a

From: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

 

Number of samples

Univariate analysis

Hazard ratio

95% CI

P -value b

All breast tumor samples

65

6.80

1.35 to 35.26

0.009

HR+/HER2− subclass

30

4.81

N/A

0.03

Luminal A subclass (HR+, HER2−, SBR1 or SBR2)c

19

3.75

N/A

0.05

Luminal B subclass (HR+, HER2+ and/or SBR3)c

17

1.69

0.07 to 17.12

0.96

  1. a95% CI, 95% confidence interval; HER2, Human epidermal growth factor receptor 2; HR+, Hormone receptor–positive (estrogen receptor (ER) and/or progesterone receptor (PR)); miR, MicroRNA; N/A, Not applicable as there is no relapse event in the low miR-125b-5p expression level group; SBR, Scarff-Bloom-Richardson grade. b P < 0.05 was considered significant. cSubclasses of breast cancer were determined using immunohistological (ER, PR, HER2) and SBR grades according to the St Gallen recommendation [38].